

GcMAF Triumphs Over Disease But Not Over Institutional Evil

By David Noakes



Philip Beales

Laurence-Moon-Bardet-Biedl syndrome (LMBBS) is a rare genetic disorder in which the body does not make cilia properly (cilia are microscopic “hairs” that perform a number of functions including cell signaling) and there is no cure. The symptoms are similar to Chronic Fatigue Syndrome; you can barely get out of bed and have little hope of holding a job down, you usually go blind by your mid-twenties, often suffer from a poor immune system, and can have kidney problems often along with chronic obesity.

Nigel Robson is the father of two young adults with LMBBS. He asked Immuno Biotech – the producer of GcMAF – if GcMAF would help, to which I (its CEO) replied "I have no idea, but it has no side effects, never does harm, and you have nothing to lose by trying." GcMAF is, after all, a human protein, produced in every healthy person’s body, and frankly a human right. It successfully treats fifty diseases and all tumor cancers (which is 90% of cancers). It has no side effects.

Nigel gave it to himself first. To his surprise, in two weeks it got rid of severe chronic acne he had had on his back for 40 years.

In February 2014, he gave it to his son and daughter. Two months later they had normal energy levels, got themselves jobs, and places in further education. Nearly all symptoms of the disease had disappeared. More surprisingly, Nigel was able to track slow improvements in their macular degeneration: their eyesight was improving.

Quite excited, Nigel contacted the LMBBS Society (www.lmbbs.org.uk) in Britain. A scientist himself, he asked if he could make a presentation at the annual conference so that the 300 other people with the disease in Britain could get their lives back too. Although he had previously attended the conference, the Society flatly refused. Immuno Biotech then approached the Society, willing to provide the GcMAF without charge, as nearly all sufferers have no income. The LMBBS Society refused Immuno Biotech’s request to make a presentation, and also said that Immuno Biotech representatives would be thrown out of the conference if they even attended.

So, the company had a meeting with Professor Philip Beales, Britain's only LMBBS

Professor, at the University College of London (UCL). Four scientists from his side, two from Immuno Biotech, eight people in total, met. Professor Beales agreed that he would test GcMAF on mice with LMBBS. Immuno Biotech was disappointed as it had hoped there would be a possibility to provide human patients with GcMAF soon, in order to relieve their suffering as quickly as possible.

Six months later, Nigel produced a scientific poster showing the results of GcMAF on his children, and the Ciliopathy scientific conference at the Institute Pasteur in Paris agreed to publish it. LMBBS is the worst of the Ciliopathy diseases. Nigel Robson and I both attended the conference, which was held 18-21st November 2014. I offered scientists at the conference to accept GcMAF *without charge* to research why it has a positive effect on LMBBS' symptoms.

On the second morning, I was approached by Professor Philip Beales and two security men, and Professor Beales directed the security men to remove me from the conference. Professor Beales stated it was because I had been trying to sell the GcMAF. I explained that was untrue, but Professor Beales persisted in having me leave the conference. I asked Beales if he had ever grown and tested those mice. The answer was *No*. Afterwards Immuno Biotech emailed all 180 Scientists who had attended the conference, offering each and every one of them GcMAF without charge. Not one bothered to reply.

And that is where it ended.

Over a year later, Professor Beales and the LMBBS society are to all appearances still concealing GcMAF from sufferers, as it appears that they have not conducted any research on GcMAF nor published any information concerning it, thus preventing sufferers from learning about the hope they might have with GcMAF. Unfortunately, though, such rejection is a typical experience for Immuno Biotech. Vested interests are continually blocking the company's path and condemning people to lives with disease, or, in the case of cancer, condemning sufferers to death. It is important to remember that not all companies are bad companies, many truly do care about their customers' health and wellbeing.